key: cord-0965452-vfxxobsz authors: Manolache, N.G.; Ursachi, V.; Scohy, A.; Desmet, C.; Yombi, J.C.; Toukap, A. Nzeusseu; Stoenoiu, M.S. title: Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases date: 2021-12-15 journal: J Infect DOI: 10.1016/j.jinf.2021.12.006 sha: 49fe24736988cef14f8331fa6ed551f1e11901ed doc_id: 965452 cord_uid: vfxxobsz nan We aimed to explore the Ab response to SARS-CoV-2 following complete vaccination in 231 patients suffering from immune-mediated or inflammatory rheumatic diseases (IMID) followed at Cliniques Universitaires Saint-Luc and to assess factors predicting a suboptimal humoral response to vaccination in at-risk patients treated with disease modifying antirheumatic drugs (DMARD). Two different electrochemiluminescent immunoassays were used to detect total antibodies in human serum: Elecsys anti-SARS-CoV-2 qualitative immunoassay using recombinant nucleocapsid antigen (anti-N) and Elecsys anti-SARS-CoV-2 S quantitative immunoassay using spike protein RBD (anti-RBD) (Roche Diagnostics GmbH, Mannheim, Germany). The two tests were carried out simultaneously, the presence of anti-N antibodies indicating post infection immunity. According to the manufacturer, a result was considered positive if the cut-off index was ≥1.0 for anti-N or ≥0.8 U/mL for anti-RBD. Values of anti-RBD Ab were converted to BAU/mL. (Figure 1 ). Non-responders were equally distributed across all age categories ( Figure 2 ) and according to quintiles of anti-RBD Ab titers (Figure 1) . Age, gender, type of rheumatic disease, disease duration, comorbidities, previous COVID-19 infection and treatment (glucocorticoids, biotherapy, synthetic DMARD) were not significantly associated with optimal humoral response after vaccination. In contrast, in patients receiving viral vector vaccines, the percentage of non-responders (30.6%) was twice higher than in patients receiving mRNA vaccine (15.2%). In multivariate logistic analysis, humoral response remained significantly associated with vaccine type (15% non-responders, mRNA vaccines; 31% non-responders, viral vector vaccines, p=0.02) when controlled for age, treatment and time between vaccination and Ab dosage. In our cohort, 5 patients were treated by anti-CD20/anti-CTLA4 biotherapy associated with methotrexate (n=4) or with mycophenolate mofetil (n=1). Three out of them developed a good humoral response (anti-RBD Ab: >250 BAU/ml, n=2 and 145 BAU/ml, n=1, respectively) while a poor response was observed in the two others (anti-RBD Ab: 58.8 BAU/ml, and 0 BAU/ml, respectively). Patients treated with methotrexate developed a humoral response similar to those without methotrexate (anti-RBD Ab: 215.6±66.2 BAU/ml, 136 patients treated with methotrexate vs. 214.5±77.4 BAU/ml, 95 patients without methotrexate). In conclusion, 82% of patients with rheumatic disease developed an optimal humoral immune response following completion of anti-SARS-CoV-2 vaccine series. We confirm that the seroconversion rates are lower in IMID patients than previously reported in healthy controls or in health care workers in Belgium (3) but higher than those in kidney transplant recipients (4) . The mRNA vaccines were associated with optimal humoral response in 85% of patients and viral vector vaccines in only 69% of patients. Therefore, the dosage of anti-RBD Ab helps to identify patients with a poorer response in whom an additional dose of vaccine or monoclonal antibodies administration may be needed in order to ensure optimal protection against severe COVID-19. In recent studies, certain therapies (anti-TNF, anti-IL17, anti-IL6, anti-IL12/23) seem not to impact seroconversion rates while others (anti-CD20, anti-CTLA-4) result in poorer responses in patients treated with immunosupressors for different rheumatic and non-rheumatic diseases (2, 5) . Furthermore, we confirm a good response to vaccination in patients treated with TNF blockers, anti-IL 17, anti-IL6, anti-12/23 therapies and observed a poor response in patients treated with anti-CD20/anti-CTLA-4 although numbers are low (n=5). Conflicting results were reported in patients using methotrexate (5, 6) . We did not found that methotrexate hampers humoral response to vaccine in our cohort. The current study has limitations. First, no data on cellular immunity are available. However, antibody response correlates well with T-cell mediated immunity (7) . Second, all patients were followed in a tertiary care centre. Third, the results cannot be necessary extrapolated in the context of different strategies, access, timing of SARS-CoV-2 vaccination throughout the world. Besides age, treatment, other unknown factors may influence the response to vaccination. However, our data suggest that monitoring the anti-RBD antibody response is feasible (1) and may identify patients with poor response to vaccination and therefore Antibody titers and protection against a SARS-CoV-2 infection Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 Antibody Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease